You are now leaving www.klisyrihcp.com
You are now leaving KlisyriHCP.com and will be directed to an independent, third-party website. The Privacy Policy and the Terms of Use of the destination website will apply.
Quick Links
KLISYRI is a microtubule inhibitor indicated for the topical treatment of actinic keratosis of the face or scalp
KLISYRI may cause eye irritation. Avoid transfer of the drug into the eyes and to the periocular area during and after application. Wash hands immediately after application. If accidental exposure occurs, instruct patient to flush eyes with water and seek medical care as soon as possible.
Chart adapted from Focused update to the Guidelines of Care
for the Management of Actinic Keratosis: Journal of the American Academy of Dermatology
(2022).
This chart is not intended to suggest superiority, comparability, or
interchangeability among AK treatments.
*For patients with AKs, nonsteroidal
anti-inflammatory drugs (NSAIDs) carry a black box warning for cardiovascular and
gastrointestinal side effects.
AK: actinic keratosis; AAD: American Academy of
Dermatology.
Chart adapted from Focused update to the Guidelines of Care
for the Management of Actinic Keratosis: Journal of the American Academy of Dermatology
(2022).
*From baseline to assessment.
†Complete clearance of all AKs within a
defined field.
‡At least a 75% reduction in AKs in a predefined field.
Additional
outcomes: Investigator global improvement index (participants rated as “completely improved’
by the investigator); Participant global improvement index (participants self-assessed as
“completely improved”); and Adverse Events.
Important Safety Information
KLISYRI is a microtubule inhibitor indicated for the topical treatment of actinic keratosis of the face or scalp.
KLISYRI may cause eye irritation. Avoid transfer of the drug into the eyes and to the periocular area during and after application. Wash hands immediately after application. If accidental exposure occurs, instruct patient to flush eyes with water and seek medical care as soon as possible.
Local skin reactions, including severe reactions (erythema, flaking/scaling, crusting, swelling, vesiculation/pustulation, and erosion/ulceration) in the treated area can occur after topical application of KLISYRI. Avoid use until skin is healed from any previous drug, procedure, or surgical treatment. Occlusion after topical application of KLISYRI is more likely to result in irritation.
The most common adverse reactions (incidence ≥2%) were local skin reactions, application site pruritus, and application site pain.
To report an adverse event or product complaint, call or email: Medical Affairs and Customer Relations • Phone: 1-866-665-2782 • Fax: 510-595-8183 • Email: almirallmc@eversana.com
Important Safety Information
KLISYRI is a microtubule inhibitor indicated for the topical treatment of actinic keratosis of the face or scalp.
KLISYRI may cause eye irritation. Avoid transfer of the drug into the eyes and to the periocular area during and after application. Wash hands immediately after application. If accidental exposure occurs, instruct patient to flush eyes with water and seek medical care as soon as possible.
Local skin reactions, including severe reactions (erythema, flaking/scaling, crusting, swelling, vesiculation/pustulation, and erosion/ulceration) in the treated area can occur after topical application of KLISYRI. Avoid use until skin is healed from any previous drug, procedure, or surgical treatment. Occlusion after topical application of KLISYRI is more likely to result in irritation.
The most common adverse reactions (incidence ≥2%) were local skin reactions, application site pruritus, and application site pain.
To report an adverse event or product complaint, call or email: Medical Affairs and Customer Relations • Phone: 1-866-665-2782 • Fax: 510-595-8183 • Email: almirallmc@eversana.com
References:
1. Eisen DB, Dellavalle RP, Frazer-Green L,
Schlesinger TE, Shive M, Wu PA. Focused Update: Guidelines of care for the management of
actinic keratosis. JAAD. 2022. 2. Blauvelt A, Kempers
S, Schlesinger T, et al. Tirbanibulin ointment 1% for actinic keratosis (AK): pooled data
from two phase 3 studies. Presented at: 40th Annual Fall Clinical Dermatology Conference
(Fall CDC 2020); Virtual Congress; October 29-November 1, 2020.
This site is intended for US audiences only.
KLISYRI® is a registered trademark of Almirall, LLC. © Copyright 2023. All Rights Reserved. Almirall, LLC, 101 Lindenwood Drive, Suite 200, Malvern, PA 19355 US-TIRBA-2300013 03/2023
Qualified U.S. healthcare professionals who are practicing medicine in the U.S. are invited to register, should they wish to receive information about KLISYRI®.
KLISYRI® is a registered trademark of Almirall, LLC. © Copyright 2023. All Rights Reserved. Almirall, LLC, 101 Lindenwood Drive, Suite 200, Malvern, PA 19355 US-TIRBA-2300013 03/2023
Get Updates
Full Prescribing Information
